secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0000950170-25-003290
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports $108.5M preliminary cash; receives $2.5M from TG Therapeutics, issues shares
--------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents, and restricted cash of ~$108.5M as of Dec 31, 2024, before $2.5M TG payment in Jan 2025.
- Expects cash runway into second half of 2026, sufficient to fund two wholly owned programs through Phase 1 data readouts.
- On Jan 6, 2025, received $2.5M deferred cash payment from TG Subsidiary and issued 220,712 shares of common stock.
- The payment and shares relate to the January 2024 License Agreement for non-oncology applications of allogeneic CAR T therapy azer-cel.
- These estimates are preliminary and subject to audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/0000950170-25-003290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/dtil-20250106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer